 TRACON Pharmaceuticals reported that it ended its second-quarter 2021 with cash and equivalents of 25.6 million as of June 30, 2021, which doesnt include proceeds from its 15 million underwritten public offering in July. The company noted it now has sufficient funds to sustain its operations into 2023. 